Patricia Van Arnum
This is the bio for Patricia Van Arnum, senior editor of Pharmaceutical Technology magazine.
Patricia Van Arnum
Executive Editor
732.346.3072, pvanarnum@advanstar.com
Patricia Van Arnum, executive editor, covers active pharmaceutical ingredients (APIs), intermediates, fine chemicals, advances in process R&D, formulation development, and finished drug-product manufacturing for Pharmaceutical Technology. She also is editor of Sourcing and Management, a monthly newsletter of Pharmaceutical Technology covering sourcing, the pharmaceutical supply-chain, API synthesis and manufacturing, and formulation development and finished drug-product manufacturing. Patricia has 20 years of experience as a business and science journalist and editor, which includes 17 years of experience covering the pharmaceutical and fine-chemicals industries. Patricia was formerly executive editor of Chemical Market Reporter (now ICIS Chemical Business) and was with CMR and ICIS from 1995–2005. She joined Pharmaceutical Technology as a senior editor in January 2006. She holds undergraduate degrees in chemistry, economics, and political science. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, the American Medical Writers Association, and the American Association for the Advancement of Science.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
